RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
A Dubois, N Furstoss, A Calleja, M Zerhouni, T Cluzeau… - Leukemia, 2019 - nature.com
Chaperone-mediated autophagy (CMA) is a highly selective form of autophagy. During
CMA, the HSC70 chaperone carries target proteins endowed with a KFERQ-like motif to the …
CMA, the HSC70 chaperone carries target proteins endowed with a KFERQ-like motif to the …
The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with …
P Miltiades, E Lamprianidou, TP Vassilakopoulos… - Clinical Cancer …, 2016 - AACR
Purpose: Azacitidine is the mainstay of high-risk myelodysplastic syndromes (MDS) therapy,
but molecular predictors of response and the mechanisms of resistance to azacitidine …
but molecular predictors of response and the mechanisms of resistance to azacitidine …
[HTML][HTML] Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation
P Wang, D Ma, J Wang, Q Fang… - International …, 2015 - spandidos-publications.com
Heme oxygenase-1 was reported previously as a resistance target on acute myelocytic
leukemia (AML). We found that HO-1 was resistant to 5-azacytidine (AZA) treatment of …
leukemia (AML). We found that HO-1 was resistant to 5-azacytidine (AZA) treatment of …
骨髓增生异常综合征去甲基化治疗的研究新进展
王化泉， 邵宗鸿 - 中国肿瘤临床, 2015 - cjco.cn
表观遗传学异常是骨髓增生异常综合征(myelodysplastic syndromes, MDS)
发病的重要机制之一, DNA 甲基化异常是MDS 最常见的表观遗传学改变. 抑制DNA …
发病的重要机制之一, DNA 甲基化异常是MDS 最常见的表观遗传学改变. 抑制DNA …
[HTML][HTML] Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS/hypoproliferative AML
X Chen, Y Wang, Y Zang, Z Wei, W Zhang, X Wei… - Medicine, 2023 - journals.lww.com
Background: This study aimed to explore the effects of recombinant human thrombopoietin
(rhTPO) on platelet recovery in decitabine, cytarabine, aclarubicin, and G-CSF (DCAG) …
(rhTPO) on platelet recovery in decitabine, cytarabine, aclarubicin, and G-CSF (DCAG) …
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive …
P Diamantopoulos, K Zervakis… - Anticancer …, 2015 - ar.iiarjournals.org
Background/Aim: The hypomethylating agent 5-azacytidine has been the standard-of-care
for patients with higher-risk myelodysplastic syndrome (MDS) during the past few years. Its …
for patients with higher-risk myelodysplastic syndrome (MDS) during the past few years. Its …
[HTML][HTML] Epigenetic modification suppresses proliferation, migration and invasion of urothelial cancer cell lines
P Brockmeyer, B Hemmerlein - Oncology Letters, 2016 - spandidos-publications.com
Epigenetic approaches offer additional therapeutic options, including apoptosis induction,
modification of cell cycle regulating proteins and the re‑expression of pharmaceutical …
modification of cell cycle regulating proteins and the re‑expression of pharmaceutical …
Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients
L Del Corso, L Biale, EL Parodi, R Russo… - International journal of …, 2017 - Springer
Background Deferasirox (DFX) is used to reduce iron levels in patients with myelodysplastic
syndrome (MDS) who develop iron overload after chronic red blood cell infusions. However …
syndrome (MDS) who develop iron overload after chronic red blood cell infusions. However …
[PDF][PDF] Aus der Klinik für Hämatologie, Onkologie und Klinische Immunologie der Heinrich-Heine-Universität Düsseldorf Direktor: Univ.-Prof. Dr. med. Rainer Haas
A Groten - docserv.uni-duesseldorf.de
Zusammenfassung Patienten mit myeloischen Hochrisiko-Neoplasien haben eine schlechte
Prognose. Die allogene Blutstammzelltransplantation (BSZT) ist die einzige Therapieoption …
Prognose. Die allogene Blutstammzelltransplantation (BSZT) ist die einzige Therapieoption …
[引用][C] Prognostische und prädiktive Faktoren für den Erfolg der allogenen Blutstammzelltransplantation nach sequentieller Konditionierung bei Patienten mit …
A Groten - Dissertation, Düsseldorf, Heinrich …